Micelle-like nanoparticles as carriers for DNA and siRNA.

Mol Pharm

Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States.

Published: February 2015

Gene therapy represents a potential efficient approach of disease prevention and therapy. However, due to their poor in vivo stability, gene molecules need to be associated with delivery systems to overcome extracellular and intracellular barriers and allow access to the site of action. Cationic polymeric nanoparticles are popular carriers for small interfering RNA (siRNA) and DNA-based therapeutics for which efficient and safe delivery are important factors that need to be optimized. Micelle-like nanoparticles (MNP) (half micelles, half polymeric nanoparticles) can overcome some of the disadvantages of such cationic carriers by unifying in one single carrier the best of both delivery systems. In this review, we will discuss how the unique properties of MNP including self-assembly, condensation and protection of nucleic acids, improved cell association and gene transfection, and low toxicity may contribute to the successful application of siRNA- and DNA-based therapeutics into the clinic. Recent developments of MNP involving the addition of stimulus-sensitive functions to respond specifically to pathological or externally applied "triggers" (e.g., temperature, pH or enzymatic catalysis, light, or magnetic fields) will be discussed. Finally, we will overview the use of MNP as two-in-one carriers for the simultaneous delivery of different agents (small molecules, imaging agents) and nucleic acid combinations.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492123PMC
http://dx.doi.org/10.1021/mp5007213DOI Listing

Publication Analysis

Top Keywords

micelle-like nanoparticles
8
delivery systems
8
polymeric nanoparticles
8
dna-based therapeutics
8
carriers
4
nanoparticles carriers
4
carriers dna
4
dna sirna
4
sirna gene
4
gene therapy
4

Similar Publications

Upconverting/magnetic Janus-like nanoparticles integrated into spiropyran micelle-like nanocarriers for NIR light- and pH- responsive drug delivery, photothermal therapy and biomedical imaging.

Colloids Surf B Biointerfaces

January 2025

Biofunctional Nanomaterials Laboratory, Centro de Física Aplicada y Tecnología Avanzada, Universidad Nacional Autónoma de México, Querétaro 76230, Mexico. Electronic address:

The integration of multiple functionalities into single theranostic platforms offers new opportunities for personalized and minimally invasive clinical interventions, positioning these materials as highly promising tools in modern medicine. Thereby, magneto-luminescent Janus-like nanoparticles (JNPs) were developed herein, and encapsulated into near-infrared (NIR) light- and pH- responsive micelle-like aggregates (Mic) for simultaneous magnetic targeting, biomedical imaging, photothermal therapy, and pH- NIR-light activated drug delivery. The JNPs consisted of NaYF:Yb,Tm upconverting nanoparticles (UCNPs) on which a well-differentiated magnetite structure (MNPs) grew epitaxially.

View Article and Find Full Text PDF

Cationic Micelle-like Nanoparticles as the Carrier of Methotrexate for Glioblastoma Treatment.

Molecules

December 2024

Department of Molecular Biology and Genetics, Faculty of Arts and Science, Necmettin Erbakan University, Konya 42090, Turkey.

In the present study, ultra-small, magnetic, oleyl amine-coated FeO nanoparticles were synthesized and stabilized with a cationic ligand, cetyltrimethylammonium bromide, and an anticancer drug, methotrexate, was incorporated into a micelle-like nanoparticle structure for glioblastoma treatment. Nanoparticles were further characterized for their physicochemical properties using spectroscopic methods. Drug incorporation efficiency, drug loading, and drug release profile of the nanoparticles were investigated.

View Article and Find Full Text PDF

Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy.

Acta Biomater

December 2024

Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108, USA. Electronic address:

Antibody-based checkpoint inhibitors have achieved great success in cancer immunotherapy, but their uncontrollable immune-related adverse events remain a major challenge. In this study, we developed a tumor-activated nanoparticle that is specifically active in tumors but not in normal tissues. We discovered a short anti-PD-L1 peptide that blocks the PD-1/PD-L1 interaction.

View Article and Find Full Text PDF

Micelle-like Nanoparticles for Drug Delivery and Magnetically Enhanced Tumor Chemotherapy.

ACS Biomater Sci Eng

December 2024

School of Life Science and Technology, Xinxiang Medical University, 601 Jinsui Road, Xinxiang 453003, China.

Using the coordination bonds between transition metal atoms and electron-rich functional groups, we synthesized two kinds of micelle-like nanoparticles. Using magnetic FeO as the core, poly(methyl methacrylate) (PMMA) and poly(acrylic acid) (PAA) brushes were grafted via activators regenerated by electron transfer for atom transfer radical polymerization (ARGET-ATRP), which formed micelle-like magnetic nanoparticles FeO/PAA-PMMA with a hydrophobic outer layer and FeO/PMMA-PAA with a hydrophilic outer layer. Both the micelle-like nanoparticles had amphiphilic properties and can be used to load hydrophilic or hydrophobic drugs.

View Article and Find Full Text PDF

The nuclear export protein of the influenza A virus (NEP) is involved in many important processes of the virus life cycle. This makes it an attractive target for the treatment of a disease caused by a virus. Previously it has been shown, that recombinant variants of NEP are highly prone to aggregation in solution under various conditions with the formation of amyloid-like aggregates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!